Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Motivation: Transcriptome-based computational drug repurposing has attracted considerable interest by bringing about faster and more cost-effective drug discovery. Nevertheless, key limitations of the current drug connectivity-mapping paradigm have been long overlooked, including the lack of effective means to determine optimal query gene signatures. Results: The novel approach Dr Insight implements a frame-breaking statistical model for the ‘hand-shake’ between disease and drug data. The genome-wide screening of concordantly expressed genes (CEGs) eliminates the need for subjective selection of query signatures, added to eliciting better proxy for potential disease-specific drug targets. Extensive comparisons on simulated and real cancer datasets have validated the superior performance of Dr Insight over several popular drug-repurposing methods to detect known cancer drugs and drug–target interactions. A proof-of-concept trial using the TCGA breast cancer dataset demonstrates the application of Dr Insight for a comprehensive analysis, from redirection of drug therapies, to a systematic construction of disease-specific drug-target networks. Availability and implementation: Dr Insight R package is available at https://cran.r-project.org/web/packages/DrInsight/index.html. Supplementary information: Supplementary data are available at Bioinformatics online.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASGARD on each cluster is related to DrInsight, a concordantly expressed genes (CEG) based, enhanced drug repurposing method compared to other signature-based searching methods30.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206 · cited 1×
“Finally, in combination with several external gene set databases such as Gene Ontology (GO) (Ashburner et al., 2000), Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000) and NCI Pathway Interaction Database (PID) (Schaefer et al., 2009), the drug–CEG interactions serve as the…”
MethodKEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232 · cited 2×
“Finally, in combination with several external gene set databases such as Gene Ontology (GO) (Ashburner et al., 2000), Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000) and NCI Pathway Interaction Database (PID) (Schaefer et al., 2009), the drug–CEG interactions serve as the skeleton to assemble…”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Self-citation
Cited by
Low, Z. Y., Farouk, I. A., & Lal, S. K. (2020) · Viruses · doi:10.3390/v12091058 · Cited by 180
“0001 and an absolute fold change of ≥4 [20].”
BackgroundYang, C. G., Zhang, H., Chen, M., Wang, S., Qian, R., Zhang, L., Huang, X., Wang, J., Liu, Z., Qin, W., et al. (2022) · eLife · doi:10.7554/elife.71880 · Cited by 180
“By contrast, relatively limited efforts have been made to standardize the generation of query signatures ( Chan et al., 2019 ; Wen et al., 2016 ; Wen et al., 2015 ).”
Drug repurposing for COVID-19: Approaches, challenges and promising candidates
Ng, Y. L., Salim, C. K., & Chu, J. J. H. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107930 · Cited by 159
Exploration of databases and methods supporting drug repurposing: a comprehensive survey
Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa003 · Cited by 131
Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes
DeMeo, B., Nesbitt, C., Miller, S. A., Burkhardt, D. B., Lipchina, I., Fu, D., Holderrieth, P., Kim, D., Kolchenko, S., Szałata, A., et al. (2025) · Science · doi:10.1126/science.adi8577 · Cited by 86
“The comparison models included two classical baseline methods: a k - nearest Hits Non-hits”
Metadata
- Authors
- Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J.
- Affiliations
- Baylor University (US)
- Baylor Scott & White Research Institute (US)
- Stephen F. Austin State University (US)
- Corresponding author
- Gu, Jinghua
- Venue
- Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-08
- Volume
- 35
- Issue
- 16
- Pages
- 2818-2826
- ISSN
- 1367-4803 (ISSN-L)
- 1367-4811
- PMC
- PMC6691331
- OpenAlex
- W2910665348
- Cited by
- 50
- References
- 57
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 12 · 2021: 7 · 2020: 13 · 2019: 3
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Bioinformatics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Index of Texas Archaeology Open Access Grey Literature from the Lone Star State (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U19AI082715)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- computational drug repurposing, drug-target interactions, cancer drug targets, breast cancer
- MeSH terms
- Software, Models, Statistical, Drug Discovery, Drug Repositioning, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing. https://app.cochat.ai/papers/10.1093/bioinformatics/btz006
- The paper
- Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J. (2019). Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing. Bioinformatics. https://doi.org/10.1093/bioinformatics/btz006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.